You could earn SmartPoints on this page!SmartPoint Coin

Health Questions & Answers



Does anyone know how taking sage for menopause symptoms might affect medication i.e. effexor, celexa, paxil, etc. ????

Barbara asked this
August 8, 2012 at 1:51 PM



Hello Barbara,

This question intrigued me so I decided to do a little bit more research on the topic. This is what I've learned.

Theoretically, sage may decrease the action of anticonvulsants. This is because the essential oils in the common sage plant contain thujone. Thujone is thought to be the ingredient in Absinthe that caused "absinthism" characterized by convulsions and hallucinations. This, however, has yet to be proven. Thujone is a GABA-antagonist, and therefore can cause convulsions and seizures when given in large doses.

This all being said, Sage has been used widely for it's healing powers and it's name is based off the latin word meaning to save. Sage also shows possible uses as an antisweating agent, antibiotic, antifungal, astringent, antispasmodic, estrogenic, hypoglycemic, and tonic through modern evidence. I would assume that the antisweating agent as well as the estrogenic benefits are what you would be using the sage for in regards to your menopause.

However, the thujone is the only compound in sage that affects the synapses and receptors in the brain.

Effexor, Celexa, and Paxil are all SSRI's. SSRI stands for selective serotonin re-uptake inhibitor and therefore would not interfere specifically with the sage and vice-versa. Also keep in mind that the amount of thujone in sage is so minute that there is little chance you'll even see the effects of the thujone speficially.

I hope this helps and if you need clarification I'll be happy to respond.

Gaby from SLN answered
August 8, 2012 at 6:17 PM
Already a member? Just sign in!

You are at least 13 years of age and agree to our terms of service.

(All fields Reqiuired)

Report Abuse

Question Tags

MenopausePet Health Medicine

Short URL:

    THRIVE Email Newsletter from HelloLife®

    Subscribe to the THRIVE Newsletter

    Site Feedback